The NeoVaCan group was launched in IrsiCaixa in mid-2019.

Our research based on multi-omics and immune characterization of cancer specimens at several layers aims to lead to personalized cancer therapies and to better understand tumour genomic and immune heterogeneity.

Our main goal is to apply cutting-edge molecular biology and next-generation sequencing (NGS)-guided procedures to the generation of robust omics data for neoepitope identification.

We work closely with IrsiCaixa’s Cell Virology and Immunology group and the Life Sciences Department of the Barcelona Supercomputing Center to translate NGS-guided and experimental analyses of neoantigen prediction and immunomarkers to the treatment of patients with cancer.